12 Feb 2025
// PR NEWSWIRE
05 Feb 2025
// PR NEWSWIRE
24 Jan 2025
// PR NEWSWIRE
Latest Content by PharmaCompass
About
Industry Trade Show
Attending
17-20 March, 2025
American Biomanufactur...American Biomanufacturing Summit
Industry Trade Show
Attending
15-16 April, 2025
Industry Trade Show
Attending
04-08 May, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
Industry Trade Show
Attending
17-20 March, 2025
American Biomanufactur...American Biomanufacturing Summit
Industry Trade Show
Attending
15-16 April, 2025
Industry Trade Show
Attending
04-08 May, 2025
12 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/allergan-aesthetics-to-launch-three-new-state-of-the-art-training-centers-in-the-us-expanding-access-to-high-quality-aesthetics-training-302374118.html
05 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/allergan-aesthetics-the-american-society-of-plastic-surgeons-asps-and-the-aesthetic-society-release-two-new-engaging-limitless-videos-celebrating-women-surgeons-302368870.html
24 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/allergan-aesthetics-unveils-new-aa-signature-program-and-immersive-booth-at-imcas-world-congress-2025-302359301.html
18 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/allergan-aesthetics-offers-free-business-education-courses-online-to-support-growing-practices-with-allergan-aesthetics-products-302307919.html
30 Oct 2024
// PRESS RELEASE
https://news.abbvie.com/2024-10-29-SkinSpirit-joins-Allergan-Aesthetics-in-Supporting-Girls-Inc-and-Empowering-the-New-Generation-of-Women-in-STEM#:~:text=IRVINE%2C%20Calif.%2C%20Oct.,explore%20career%20paths%20in%20STEM
29 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/skinspirit-joins-allergan-aesthetics-in-supporting-girls-inc-and-empowering-the-new-generation-of-women-in-stem-302289495.html
Details:
AGN-151586 (trenibotulinumtoxinE) is a first-in-class, short-acting neurotoxin, which is investigated for the treatment of Glabellar Lines. If approved, BoNT/E will be the first neurotoxin of its kind available to patients.
Lead Product(s): TrenibotulinumtoxinE
Therapeutic Area: Dermatology Brand Name: AGN-151586
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Lead Product(s) : TrenibotulinumtoxinE
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AGN-151586 (trenibotulinumtoxinE) is a first-in-class, short-acting neurotoxin, which is investigated for the treatment of Glabellar Lines. If approved, BoNT/E will be the first neurotoxin of its kind available to patients.
Product Name : AGN-151586
Product Type : Large molecule
Upfront Cash : Not Applicable
October 24, 2023
Details:
Botox Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.
Lead Product(s): OnabotulinumtoxinA
Therapeutic Area: Dermatology Brand Name: Botox Cosmetic
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Lead Product(s) : OnabotulinumtoxinA
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Botox Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.
Product Name : Botox Cosmetic
Product Type : Large molecule
Upfront Cash : Not Applicable
September 18, 2023
Details:
Juvederm Voluma™ XC (hyaluronic acid) is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Brand Name: Juvederm Volux XC
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
JUVÉDERM® VOLUX™ XC For Improvement Of Jawline Definition Now Available Nationwide
Details : Juvederm Voluma™ XC (hyaluronic acid) is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21.
Product Name : Juvederm Volux XC
Product Type : Small molecule
Upfront Cash : Not Applicable
January 18, 2023
Details:
The SkinMedica (coffea arabica) Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities. Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product.
Lead Product(s): Coffea Arabica,Caffeine,Hydrolyzed Rice Protein
Therapeutic Area: Dermatology Brand Name: SkinMedica
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Lead Product(s) : Coffea Arabica,Caffeine,Hydrolyzed Rice Protein
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SkinMedica® Launches Even & Correct
Details : The SkinMedica (coffea arabica) Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities. Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product.
Product Name : SkinMedica
Product Type : Small molecule
Upfront Cash : Not Applicable
January 17, 2023
Details:
BOTOX (OnabotulinumtoxinA) Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.
Lead Product(s): OnabotulinumtoxinA
Therapeutic Area: Dermatology Brand Name: Botox
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Lead Product(s) : OnabotulinumtoxinA
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
Details : BOTOX (OnabotulinumtoxinA) Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.
Product Name : Botox
Product Type : Large molecule
Upfront Cash : Not Applicable
November 02, 2022
Details:
BOTOX® Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.
Lead Product(s): OnabotulinumtoxinA
Therapeutic Area: Dermatology Brand Name: Botox
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Lead Product(s) : OnabotulinumtoxinA
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign C...
Details : BOTOX® Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.
Product Name : Botox
Product Type : Large molecule
Upfront Cash : Not Applicable
September 13, 2022
Details:
Data analyses of onabotulinumtoxinA (BOTOX®) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and long-term use.
Lead Product(s): OnabotulinumtoxinA
Therapeutic Area: Neurology Brand Name: Botox
Study Phase: ApprovedProduct Type: Large molecule
Recipient: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Lead Product(s) : OnabotulinumtoxinA
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : AbbVie Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data analyses of onabotulinumtoxinA (BOTOX®) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and ...
Product Name : Botox
Product Type : Large molecule
Upfront Cash : Not Applicable
July 25, 2022
Details:
VUITY, an optimized formulation of pilocarpine, established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHast™ technology, which allows VUITY to rapidly adjust to physiologic pH of the tear film.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Vuity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VUITY, an optimized formulation of pilocarpine, established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHast™ technology, which allows VUITY to rapidly adjust to physiologic pH ...
Product Name : Vuity
Product Type : Small molecule
Upfront Cash : Not Applicable
April 28, 2022
Details:
VUITY is an optimized formulation of pilocarpine, an established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHas technology, which allows VUITY to rapidly adjust to physiologic pH of the tear film.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Vuity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VUITY is an optimized formulation of pilocarpine, an established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHas technology, which allows VUITY to rapidly adjust to physiologic pH...
Product Name : Vuity
Product Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Details:
BOTOX Cosmetic (onabotulinumtoxinA), the first and only neurotoxin product approved by U.S.FDA, to temporarily improve the look of moderate to severe lines in three areas; frown lines, crow's feet and forehead lines.
Lead Product(s): OnabotulinumtoxinA
Therapeutic Area: Dermatology Brand Name: Botox
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Lead Product(s) : OnabotulinumtoxinA
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval
Details : BOTOX Cosmetic (onabotulinumtoxinA), the first and only neurotoxin product approved by U.S.FDA, to temporarily improve the look of moderate to severe lines in three areas; frown lines, crow's feet and forehead lines.
Product Name : Botox
Product Type : Large molecule
Upfront Cash : Not Applicable
April 13, 2022
Inspections and registrations
ABOUT THIS PAGE